Home
N/A
Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder
Description:
This presentation will provide a comprehensive overview of the prevalence and burden of agitation associated with schizophrenia or bipolar I disorder. The presenter will discuss appropriate treatment goals for patients experiencing agitation associated with these psychiatric conditions. The presenter will also discuss a treatment option.
Date:
Time:
[XX:XX am/pm - XX am/pm]
Location:
[name of venue]
[name of meeting room]
[City], [State]
Speakers:
[Name, Credential]
[Affiliation]
[City, State]
Sponsored by
If you are licensed in any state or other jurisdiction or are an employee or contractor of any organization or governmental
entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able
to comply with such requirements. Your name, the value, and purpose of any educational item, meal, or other items of value
you received may be reported as required by state or federal law. Once reported, this information may be publicly accessible. Thank you for your cooperation.
This is a promotional event. CME/CE credit will not be available for this session.
In compliance with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. This
promotional educational activity is brought to you by Teva Select Brands and is not certified for continuing medical education.
The speakers are presenting on behalf of Teva Select Brands and must present information in compliance with FDA requirements
applicable to Teva Select Brands.